Federal Register Notice: FDA has determined the regulatory review period for Mitsubishi Tanabe Pharma Corp.’s Stendra (avanafil) is 3,770 days for extending a patent which claims the human drug product. FDA has approved for marketing the human drug product Stendra is indicated for treating erectile dysfunction. To view this notice, click here.
